Market Overview

UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing

Related ISIS
ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium
Isis Pharmaceuticals Prices Offering of $425M Of 1.00% Convertible Senior Notes
Making Money With Charles Payne: 10/08/14 (Fox Business)

Piper Jaffray reduced its rating on ISIS Pharmaceuticals (NASDAQ: ISIS) from Overweight to Neutral and reduced its price target from $18 to $10.

Piper Jaffray noted, "The FDA just released the briefing documents for KYNAMRO's Endocrinologic and Metabolic Drugs Advisory Committee meeting this Thursday, October 18th. The surprise in the docs has to do with questions #5 and #6 relating to "malignant fibrohistiocytic tumors" as well as "hemangiosarcomas" and "hepatocellular adenomas/ carcinomas" in mice "at clinically relevant exposures." … This represents a significant change in our view of KYNAMRO's safety profile going into the panel on Thursday and lowers the potential likelihood of a positive panel vote."

ISIS Pharmaceuticals closed at $13.15 on Monday.

Latest Ratings for ISIS

DateFirmActionFromTo
Sep 2014Leerink SwannAssumesMarket Perform
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters